BCL2 and acute myeloid leukemia: This metabolic–cell cycle coupling creates a therapeutic vulnerability: simultaneous inhibition of PHGDH‐dependent one‐carbon metabolism and BCL2‐mediated apoptotic resistance may synergistically collapse survival programs in metabolically stressed AML cells [71, 72, 73, 74].